Opus Genetics is trading at $5.02, up +5.46%, with no specific driver identified. - No verified September 28 company announcement directly explains the gain; its latest listed release was September 9 clinical-trial news. - Kodiak Sciences reported results from a separate retinal-disease Phase 3 study, but available coverage does not connect that event to Opus Genetics’ move. - The provided market context is negative, so the gain runs counter to broad-market direction.